Alan

1.1 Identity, Mission & Business Model

Alan was incorporated on 10 February 2016 in Paris and became the first new independent health insurance company to receive an ACPR licence in France since 1986—a market where ten players control two-thirds of a €47.2B complementary-health premium pool. The company's name is a deliberate tribute to two Alans: Alan Turing, the father of modern computing, and Alan Watts, the philosopher of personal integration and well-being, expressing the founders' thesis that technology and human flourishing are inseparable. Alan describes itself as a "health partner" rather than merely an insurer. Its business model has two intertwined revenue streams: (1) ACPR-licensed complementary health insurance premiums priced on an equilibrium principle—the company targets zero margin between collected premiums and paid reimbursements—and (2) a per-member subscription that funds its digital platform, virtual clinic, prevention tools, and AI services. This twin-engine design is intended to remove the adversarial premium-extraction dynamic of traditional insurers and instead earn margin through platform engagement and scale economics. Alan targets French and European employers of all sizes, including large enterprises, SMEs, freelancers, and—since 2025—the French civil service. Its proposition rests on radical operational speed (70% of reimbursements in under one hour, 99% within 24 hours, and a 20-second average phone response), a fully digital member experience via a mobile app, and an expanding suite of ancillary services: a virtual clinic (Clinique Alan) open seven days a week, the Alan Play gamified wellness programme, optical ordering, physiotherapy content, and the Mo AI health assistant launched in November 2024. [CO001, CO002, CO003, CO004, CO005, CO006]

1.2 Founders, Leadership & Corporate Governance

Jean-Charles Samuelian-Werve (CEO) and Charles Gorintin (CTO) are the sole co-founders and remain executive leaders of the company a decade after launch. Samuelian-Werve previously co-founded Expliseat, the creator of the world's lightest certified economy aircraft seat; he holds an MSc in Engineering from École des Ponts ParisTech, an MBA from Collège des Ingénieurs, and membership in the French Institute of Actuaries. He was awarded the Ordre National du Mérite in 2021. Gorintin was a data science leader at Facebook, Instagram, and Twitter before Alan, focusing on social network growth and fraud; his academic credentials span École des Ponts ParisTech, ENS Paris-Saclay (Machine Learning), and UC Berkeley's Haas School of Business (Financial Engineering). Both founders are also non-operating co-founders and board members of Mistral AI, the Paris- based large-language-model company founded in April 2023 and valued at approximately €12B. Alan itself holds a minority stake in Mistral. The intertwining of insurance and AI strategy is central to Samuelian-Werve's "methodic optimist" worldview: technology can improve healthcare quality at scale, but only if paired with sound insurance and clinical operations. Alan's senior management team includes Mihaela Albu (Finance & Strategy, ex-McKinsey Associate Partner, INSEAD MBA), Paul Sauveplane (General Secretary and HRD, ex-ACPR and Inspection Générale des Finances, the architect of Alan's ACPR licensing process), Marion Bergeret (Corporate/Legal, ex-Oxford, UC Berkeley, and AI startup Snips), Laurent Guérin (Insurance, ex-French Treasury, École Polytechnique/MIT), and country GMs for France (Fabrice Staad), Belgium (Sébastien Fredeau), Spain (Yoann Artus), and Canada (Mark Goad, ex-Curv Health and OMERS Ventures). Jan Hammer of Index Ventures has been a board member since Alan's Series A in 2018. A key governance feature: founders and employees collectively hold more than 40% of Alan's capital and maintain a majority of voting rights, insulating strategy from single-investor control despite eight funding rounds totalling ~€754M. [CO007, CO008, CO009, CO010, CO011, CO012]

1.3 Funding History & Capital Structure

Alan has completed eight funding events since inception, accumulating approximately €754M in equity capital and reaching a post-money valuation of €5B as of March 2026—representing a 30% step-up from the €4B valuation set in September 2024. The fundraising arc reflects the successive de-risking of the business: early rounds with Partech Ventures, CNP Assurances, and Power Financial of Canada funded the ACPR licensing and market entry; Index Ventures led Series A and Series B to scale beyond start-ups and SMEs; Temasek (Singapore sovereign wealth fund) added Series C capital during the COVID-accelerated digital-health wave; Ontario Teachers' Pension Plan led Series E at the €2.7B mark, signalling that Alan had category-defining scale; and Belgian bank-insurer Belfius led Series F in 2024 at €4B, coupling distribution rights with capital. The March 2026 €100M round was led by Index Ventures through its growth fund and joined by new institutional investors Greenoaks (San Francisco) and Kaaf (Dubai), strategic partner Belfius, and family office SH. Business angels Tobi Lütke (Shopify CEO), Antoine Griezmann (footballer, 2018 World Cup winner), Mike Katchen (Wealthsimple CEO), and Kylian Mbappé (via Coalition Capital) participated, reflecting both Alan's cultural weight in France and its ambition as a consumer brand. Alan's balance sheet shows regulatory capital exceeding €374M—more than 3.6 times the ~€105M regulatory minimum required by ACPR for group-level operations—with the majority held in liquid deposit accounts. Reinsurance partners (Swiss Re, GenRe, CNP Assurances, Hannover Re, Belfius Insurance) further cap exposure to healthcare cost volatility. Cash reserve was reported at approximately €376M following the March 2026 close. [CO013, CO014, CO015, CO016, CO017, CO018]

1.4 Operating Metrics, Scale & Geographic Reach

Alan's ARR trajectory is the clearest signal of its momentum: from €340M in 2023 to €505M in 2024 (+48%), €785M for FY2025 (+53%), and €804M already in Q1 2026 alone against a full-year €1B target. Member count crossed one million (exactly 1,059,000 at end-2025, +52% YoY), served across 37,000+ businesses. Headcount stands at approximately 790+ as of April 2026, up from ~600 in 2024, with hiring concentrated in Canada and Belgium. France remains the dominant market, where Alan insures over 700,000 members and achieved operational profitability in 2025—a structural milestone confirming the unit economics of the French book. Net loss at group level improved from €39M in 2023 to €34M in 2024 and further to €26M in 2025, with losses as a share of ARR falling substantially. Group-level profitability is targeted by 2027. Belgium is Alan's second-largest market, with a Belfius distribution partnership giving access to millions of potential employees of Belfius's corporate clients. Spain grew members 42% in 2025 and counts HP and Volkswagen among its clients. Canada, launched commercially in early 2025, is now licensed nationwide; the Quebec rollout began in January 2026, and the company serves over 1,600 members in Canada with plans to expand to Montreal. Alan's October 2024 OSFI licence made it the first new health insurance company in Canada since 1957. Public-sector penetration has emerged as a material growth vector: in May 2025, Alan won the French Ministry of Economy and Finance complementary health tender covering up to 135,000 civil servants (potentially 300,000 with dependants). It had previously won contracts for the Prime Minister's Office and the Ministry of Ecological Transition. [CO023, CO024, CO025, CO026, CO027, CO028]

1.5 Milestones, Regulatory Standing & Risk Landscape

Alan's regulatory standing is a foundational strength. Its ACPR authorisation of 20 October 2016 (Decision n° 2016-C-72) was the first granted to a new French insurer in three decades, and the company has maintained a solvency ratio reported at ~450% in 2023—roughly double the French market average of ~241% and well above the regulatory minimum. Paul Sauveplane, who spearheaded the ACPR licensing process in 2016, remains General Secretary, providing institutional continuity on regulatory matters. The most material adverse event as of the runDate is the Almerys cyberattack disclosed on 23 May 2026. Almerys, Alan's third-party payment operator, was breached by a threat actor claiming to have accessed over 44 million records and 15 million unique Social Security numbers. For Alan members, exposed data includes civil status, date of birth, Social Security number, contract number, and insurer name; banking data, health records, and contact details were reportedly unaffected. Alan took the affected platform offline, notified ACPR and CNIL, and committed to individually informing all members whose data was compromised. As of 23 May 2026, the total number of affected Alan members remained undisclosed. This is the second major Almerys incident: the January 2024 breach alongside Viamedis exposed data of 33 million French citizens per CNIL records. Independent analysts have also questioned Alan's valuation trajectory. Matteo Carbone of the IoT Insurance Observatory called the €4B Series F valuation "unrealistic," citing premium levels and persistent losses; the counter-thesis centres on Alan's technology premium and growth curve. The valuation step-up to €5B in March 2026 while still group-loss-making will remain a diligence focal point for prospective investors. [CO032, CO033, CO034, CO036, CO038, CO039]

1.6 Exhibits

2.1 Market Boundary & Definition

Alan operates in the French complémentaire santé (complementary health insurance) market, which is structurally distinct from primary social-security health insurance (Assurance Maladie) funded through payroll contributions. Complementary health insurance covers the gap between what the national health system reimburses and actual healthcare costs—typically copayments, dental, optical, hearing aids, specialist fees above tariff, and selected mental-health services. It is financed entirely by private premiums, either through employer group ("collectif") contracts or individual ("individuel") contracts. As of 2024, ACPR and DREES confirm the French complementary health premium pool at approximately €46.5–47.2B in cotisations collectées, making it the largest complementary-only insurance market in Europe and the world. Three actor families serve this market: mutuelles governed by the Code de la mutualité (249 active in 2024, down ~one-third since 2016), institutions de prévoyance (IPs) governed by the Code de la sécurité sociale (25 active), and sociétés d'assurance governed by the Code des assurances (99 active). Market share by premium: assurance companies 56%, mutuelles 26%, IPs 18%. In the collective segment (57% of cotisations and Alan's primary hunting ground), assurance companies hold 54% and IPs hold 30%, with mutuelles at 16%. This concentration reflects both the post-ANI 2016 shift toward group contracts and decades of M&A activity driven by minimum-capital requirements. Fifty-one insurer groups account for 85% of all complementary health cotisations in 2024. The French market's defining regulatory features are: (1) the ANI 2016 reform, which since 1 January 2016 mandates all private-sector employers to offer ACPR-compliant group health coverage with at least 50% employer premium co-payment—creating the backbone of Alan's target B2B segment; (2) the Contrats responsables framework, which constrains product design by mandating minimum and maximum reimbursement levels for all compliant contracts, limiting underwriting differentiation; (3) the 100% Santé/RAC0 reform (2019–2021), which mandates zero-out-of-pocket baskets for dental prostheses, hearing aids, and glasses, increasing claims costs for all insurers; and (4) the PSC reform (Protection Sociale Complémentaire), which extends the ANI-style employer mandate to the French public sector, with implementation from 1 January 2025 for most State ministries and 1 January 2026 for the remaining ministries (Education, Higher Education, Sports) and territorial/ hospital public employers. Adjacent and excluded spend: Alan's offering does not cover primary statutory social-security contributions, long-term care (dépendance) insurance (a distinct product class in France), personal accident insurance (dommages corporels autres), or private acute-hospital insurance as a standalone. Alan's platform subscription fees (12–14% of premium equivalent) fund digital services and are not counted in official complementary health premium statistics—creating a modest dual-revenue layer on top of insurance cotisations. Internationally, Alan is active in Belgium's supplementary health insurance market (~€2.5B GWP), Spain's voluntary health insurance (VHI) market (size requires separate estimation—see evidence gap GM001), and Canada's employer-supplemental benefits market (~CAD $55.9B in 2022 premiums). Each market carries distinct regulatory licensing (FSMA/Belgium, DGSFP/Spain, OSFI/Canada), distinct product conventions, and distinct incumbent dynamics. Belgium and Spain are currently loss-making for Alan, while France achieved operational profitability in 2025. [CM001, CM002, CM003, CM004, CM005, CM006]

2.2 Market Sizing — TAM, SAM, and SOM

The Total Addressable Market (TAM) for Alan is the universe of private complementary health insurance premiums in the geographies where it is licensed. In France, the single largest market, ACPR Analysis & Synthesis No. 178 (December 2025) confirms €47.2B in health-only complementary premiums for 2024; DREES's parallel 2025 annual report records €46.5B in cotisations for the same year (methodology differences explained by ACPR including certain border activity). France Assureurs reports €46.8B in health-segment cotisations with +7.6% growth in 2024. All three primary sources converge on a €46–47B French complementary health premium pool growing at roughly 7–8% annually. Belgium adds approximately €2.5B in supplementary health gross written premiums (KPMG 2024 study), of which €1.5B is handled by private insurers and €1B by mutualities. The Belgian market is mature with low annual growth (~3.6% CAGR 2018–22). Spain's total health insurance market is estimated at approximately $41.77B USD in 2024 by Market Research Future; however, this figure includes the public Sistema Nacional de Salud, which is tax-funded, not insurance-premium-funded. The relevant private VHI/complementary segment in Spain is substantially smaller—Alan has not publicly disclosed a Spain-specific market size, and no authoritative regulator-published figure for Spanish private complementary premiums alone was identified (see evidence gap GM001). Canada's private employer supplemental benefits market collected CAD $55.9B in premiums in 2022 (CHLIA via HelloSafe), 90% via group plans; this market is heavily concentrated (Manulife at 20%, Sun Life at 15%) and structurally different from French complémentaire santé. The Serviceable Available Market (SAM)—the portion Alan can realistically target with its B2B employer-group digital proposition—centres on collective (group) employer contracts in France, Belgium, and Spain. In France, group/collective contracts represent 57% of total complementary health cotisations, implying a French group SAM of approximately €26.7B. Belgium's collective supplementary health segment totals approximately €950M in GWP. Spain's employer-group VHI share is not precisely quantified but is estimated at €2–4B based on proportionate methodology (see evidence gap GM001). Combined France+Belgium+Spain B2B SAM: approximately €28–32B. Canada's group market (~90% of CAD $55.9B = ~CAD $50B) is large but Alan is in an early-stage commercial footprint (1,600+ members) and faces dominant incumbents; it is excluded from the near-term SAM calculation. Alan's Serviceable Obtainable Market (SOM) is evidenced by its current and target ARR trajectory. With €785M ARR in 2025 across France, Belgium, and Spain, and targeting €1B in 2026, Alan represents approximately 2.5–3.3% of the combined France+Belgium B2B employer group premium SAM. CEO Jean-Charles Samuelian-Werve has confirmed the company has not yet reached 1% market share in any of its operating markets—consistent with the math: €785M against a ~€47B French market implies ~1.7% penetration on total premiums, and less when Alan's 12–14% platform subscription margin is excluded from the premium-equivalent comparison. The SOM growth path depends on annual contract churn in the incumbent base, Alan's B2B sales capacity, and speed of PSC reform implementation for the public-sector segment. A scenario analysis using 40% ARR CAGR (management guidance) implies a €3–5B ARR SOM within five years—still below 10% of the French+Belgian employer group market. [CM001, CM016, CM017, CM018, CM019, CM020]

2.3 Buyer Landscape & Segment Map

Alan's primary buyer is the employer—the HR director or business owner who selects and procures group complementary health coverage for employees. In the French group market, the employer is both budget owner and the contracting party, paying at least 50% of the "cotisation d'équilibre" under ANI 2016. The employee (end user and insured member) does not usually select their insurer but experiences the product directly through Alan's mobile app, reimbursement speed, virtual clinic, and prevention features. The payer structure thus separates procurement (employer) from consumption (employee), creating a dual buyer-user dynamic where Alan must win employer trust on price and compliance while winning employee satisfaction on experience. Segment structure in France operates across five main employer types: (1) SMEs (1–250 employees)— Alan's highest-volume segment, where administrative simplicity and speed-of-onboarding are decisive; (2) mid-market and large enterprises (250+ employees)—now a growing priority for Alan, which onboarded HP and Volkswagen in Spain and multiple French large accounts; (3) public-sector bodies— emerging since the PSC reform; Alan won the Ministry of Economy and Finance tender (135,000 agents, up to 300,000 with dependants) in May 2025, validating its ability to bid on large-scale procurement tenders; (4) freelancers and self-employed (travailleurs indépendants)—a segment Alan has served since 2017, using individual rather than group contracts; (5) retirees—a newly addressed segment as of January 2025, with TechCrunch reporting 750,000 new retirees annually in France. In Belgium, Alan's go-to-market is shaped by its Belfius distribution partnership: Belfius acts as a trusted intermediary and distribution channel, directing its own 7,000+ employees and a pipeline of corporate and institutional clients to Alan. This partner-channel model reduces Alan's direct sales cost but introduces dependency on the Belfius relationship for Belgian growth. In Spain, Alan has targeted large multinational enterprises (HP, Volkswagen documented) and is expanding to SMEs. In Canada, Alan is in early commercial stage (1,600+ members as of Q1 2026), where the buyer profile mirrors France—employers seeking digital-first group supplemental benefits. Adoption triggers vary by segment: for SMEs, the trigger is typically administrative pain relief (instant reimbursements, zero paper) and competitive pressure for talent; for large enterprises, it is a mix of employee experience benchmarking, ESG/well-being reporting requirements, and procurement cycle timing; for public-sector bodies, the PSC reform creates a mandated procurement moment. The switching cost for existing group contracts is moderated by the French annual-switch right (résiliation infra-annuelle since 2020), though inertia remains because HR teams must communicate changes, migrate employee data, and manage IT-system integrations. Alan's AI-assisted onboarding and digital HR tools are designed explicitly to lower this switching friction. [CM009, CM010, CM011, CM029, CM030, CM031]

2.4 Growth Drivers, Adoption Friction & Structural Constraints

The French complementary health market's growth is structurally underpinned by the ANI 2016 mandate, which created a predictable, stable premium pool of employer group contracts and drove group cotisations to 57% of all complementary health premiums. The PSC reform (2025–2026) extends this logic to the French public sector—3.5 million civil servants across State, territorial, and hospital employers— opening a large, previously untapped employer segment where Alan has already demonstrated competitive success. Medical inflation further sustains premium growth: France Assureurs confirms +7.6% cotisations growth in 2024, driven by both tariff increases and a rising number of contracts. DREES records +8.2% growth, the highest since 2012, with 2024 being the first year the overall technical result turned positive since 2011, signalling that insurers have begun restoring margins after several loss-making years. Digital transformation is a secular demand driver: Alan's Q4 2024 shareholders' letter documents 81% of patients chose AI-assisted consultation (Mo) over traditional doctor interaction; 35% weekly engagement on Alan Walk (gamified prevention); and a 50% productivity improvement in the sales team from AI tools. Deloitte's 2024 Belgian health insurance consumer study confirms 27% of young Belgian adults (25–34) use health apps, driving insurer product innovation toward digital-native platforms. European Insurtech market is growing at an estimated CAGR of 52% through 2031, confirming investor and operator appetite for digital disruption of traditional insurance (Cognitive Market Research 2024). The most material structural headwind is the 100% Santé/RAC0 reform, implemented 2019–2021 but continuing to push claims higher. DREES's English-language study confirms premiums rose 12% at age 85 and 7% at age 60 for individual contract holders, CHI organisations paid an extra €2.1B for covered items, and the use of hearing aids rose 75% (and dental prostheses/glasses 17%) between 2019 and 2021. This reform structurally increases loss ratios for all complementary health insurers, and the claims inflation is continuing as coverage awareness grows; the DREES 2025 report records that prestations grew +5.4% in 2024, faster than core healthcare inflation. For Alan, which targets equilibrium premiums (zero technical margin on insurance), higher structural claims costs mean the subscription margin must bear more burden. A second headwind is the concentration and entrenchment of incumbents. Fifty-one groups control 85% of the French complementary health market. The top institutions de prévoyance (Malakoff Humanis, Klesia, AG2R La Mondiale) dominate the collective segment through branch-level agreements (accords de branche) that designate a specific insurer for an entire professional sector—locking employers into incumbents regardless of price or service quality. These mandatory designation clauses were partially struck down by the Conseil Constitutionnel in 2013 but voluntary designation arrangements remain common and create structural inertia. A third headwind is multi-jurisdictional regulatory complexity. Alan's international expansion requires maintaining separate ACPR (France), FSMA (Belgium), DGSFP (Spain), and OSFI (Canada) licenses—each with distinct solvency requirements, product mandates, and data privacy rules. The Almerys cyberattack of May 2026, involving Alan's third-party payment operator, introduced fresh compliance risk under both ACPR and CNIL frameworks and underscores the operational risk of relying on third-party infrastructure in a heavily regulated market. Finally, Alan's valuation at €5B while group-loss-making and <1% market share has attracted external scrutiny from analysts such as Matteo Carbone (IoT Insurance Observatory), who cited the valuation as "unrealistic" relative to premiums and persistent losses, creating a diligence-sensitivity headwind for any primary transaction or secondary sale. [CM003, CM005, CM006, CM007, CM008, CM015]

3.1 Competitive Landscape: Structure and Segmentation

The French complementary health insurance (CHI) market is highly concentrated. The five largest groups by 2024 direct cotisations are: Groupe VYV including Harmonie Mutuelle (€6.12B), Malakoff Humanis (€3.82B), AXA France (€3.57B), Alliance Klesia-Generali (€2.84B), and Groupama (€2.83B). Together, the top 51 groups capture 85% of all CHI cotisations. Alan's ARR of €785M for FY2025 places it outside the top-ten ranked organisms but growing at 53% YoY versus a sector average of 3–5%. This analysis organises competitors into three tiers. Tier 1 comprises large-scale incumbent mutual societies (mutuelles) and commercial insurers with deep broker-led distribution, mandatory CCN sectoral relationships, and capital reserves far exceeding Alan's. Tier 2 includes digital-native challengers and specialised health benefit platforms that overlap with Alan on specific features or buyer segments. Tier 3 covers adjacent care-navigation and employer-safety players whose service scope intersects with Alan's non-insurance health features but who do not compete in the insurance purchasing decision. Alan's competitive strategy is to capture the employer SME segment by offering a superior product experience at roughly comparable pricing, rather than competing on cost or distribution breadth where incumbents hold structural advantages. The employer-group (collectif) segment represents approximately 57% of total French CHI premiums (≈€26.7B of €46.8B in 2024). Alan's primary attack surface is this collective segment, particularly among tech companies, startups, and mid-market SMEs that value digital experience, transparency, and integrated wellbeing services over historical broker relationships. [CP001, CP002, CP003, CP004, CP005, CP043]

3.2 Incumbent Mutual Societies and Commercial Insurers

Malakoff Humanis is France's second-largest CHI group by cotisations. Its 2025 results showed group insurance revenue of €8.37B (health: €4.22B, +5% YoY), a net result of €231M, and a solvency ratio of 270%. The group insures approximately 10 million people across health and prévoyance and serves around 400,000 enterprise clients across 83 professional branches, many of which are bound by CCN-level agreements. Its health redistribution rate of 84% — meaning €84 paid in claims per €100 collected — is a transparency metric that incumbents promote as evidence of mutualised value. Malakoff has an employer extranet for digital contract management but lacks an integrated wellbeing or AI health assistant platform. Distribution is predominantly broker-mediated. Harmonie Mutuelle, part of Groupe VYV (the number-one CHI group), protects five million members and serves approximately 88,000 enterprise clients, 92% of whom recommend it. VYV's total membership of 10.6 million makes it the largest mutual network in France. Harmonie offers three enterprise coverage tiers — Économique, Confort, and Optimal — and accesses a care-provider network (Kalixia) for optical, dental, and audio. Its mutualiste governance reinvests surplus rather than paying dividends, supporting stability but limiting product agility. Digital tools include an employer extranet and member app but no AI health assistant. AG2R LA MONDIALE is a 115-year-old joint employer-union paritaire group. Its Flexéosanté SME product starts at approximately €19.77/month with 6 coverage levels and optional assistance and wellness packs. AG2R's structural advantage lies in administering mandatory CCN health coverage for numerous sectors, creating distribution lock-in that is difficult to displace outside contract renewal cycles. A digital employer portal exists but clinical and AI health services are absent. MGEN (Mutuelle Générale de l'Éducation Nationale) covers four million people, almost exclusively in the French public sector (Education nationale, Enseignement supérieur, Jeunesse et Sports). From 1 May 2026, MGEN became the mandatory PSC (Protection Sociale Complémentaire) provider for all active agents in those ministries, with a base premium of €75.40/month (employer covers at least 50%). This PSC mandatory designation represents structural lock-in that Alan cannot replicate for this specific public-sector segment without winning a national tender. Apicil is a paritaire group based in south-east France with €4.03B total revenue in 2025, 2.2 million principal insured, 57,573 enterprise clients, and a solvency ratio of 182%. Health and prévoyance account for €1.5B of total revenue. The group emphasises RSE and regional proximity as differentiation. No AI-driven health platform is evident in its public product pages. AXA France is the third-largest CHI group by cotisations (€3.57B in 2024, +15.2% YoY), with 70.7% in the collective segment. AXA's Q1 2026 group-level life and health premiums reached €16.5B (+8%). AXA has the brand recognition, solvency capital, and multi-product cross-sell capability to challenge Alan at the large enterprise and public-sector contract level. Its digital employer portal is more advanced than most mutual societies, and it is actively investing in health digitalisation, though its primary competitive posture remains large-enterprise and individual market. Generali, operating via the Alliance Klesia joint venture, is the fourth-largest CHI group (€2.84B cotisations 2024, +14.5% YoY; 66.7% collective). The Generali Group recorded a record operating result of €8.0B in 2025 (+9.7%) and a solvency ratio of 219%. The Klesia partnership gives access to paritaire sectoral CCN distribution, complementing Generali's commercial insurer capital base. No differentiated digital experience is publicly prominent. [CP006, CP007, CP008, CP009, CP010, CP011]

3.3 Digital-Native Insurtech and Adjacent Digital Health Players

Doctolib is France's dominant care-navigation platform, holding approximately 90% market share in online medical appointment booking. In 2024 it reported ARR of €348M (+22.5% YoY) and carried a valuation of approximately $6.4–6.5B, having raised over $866M in total. Doctolib's business model is B2B SaaS subscriptions for healthcare providers — GPs, specialists, clinics, and hospitals — with patients using the platform for free. It is not a complementary health insurer and does not hold an ACPR insurance licence. Its 2026–2029 strategic roadmap focuses on clinical AI, practice-management financial services, and a potential IPO; entering insurance is not flagged. Doctolib and Alan operate in overlapping care-access territory — Alan provides teleconsultation, appointment access, and health guidance within its own platform, which partly duplicates Doctolib's patient-side booking features. The competitive relationship is best characterised as adjacent and partially substitutable in care-navigation features, with potential for complementarity (Alan members could book via Doctolib) but no direct insurance purchasing competition. Lifeaz is a French connected-defibrillator (AED) company founded in 2015. In February 2026 it completed a €13M funding round (€20M total raised), employs 40 people, and has installed more than 25,000 defibrillators across France, including a partnership with the Croix-Rouge française. Lifeaz is not a health insurer. It occupies the employer occupational-safety benefit stack — an employer may deploy Lifeaz AEDs alongside an Alan group health contract with no conflict. The relationship is adjacent and complementary; Lifeaz's investor Mutuelles Impact (backed by the Mutualité Française via XAnge) connects it to the incumbent mutual ecosystem rather than to the insurance challenger space. In the digital insurtech category more broadly, Seedtable tracks only 6 insuretech startups in France in 2026 with aggregate funding of approximately $243M. Alan captures the large majority of that capital and is the only ACPR-licensed full-stack health insurer among them. Other digital players (Wemind for freelancers, Lovys for multi-risk bundles) are primarily brokers or white-label resellers without their own insurance licences, competing in Alan's individual and TNS segments but at minimal scale compared to the incumbent market. [CP021, CP022, CP023, CP024, CP025, CP037]

3.4 Comparative Capabilities, Pricing, and Switching Friction

Alan's primary differentiation versus incumbents is threefold: technology-led processing speed, integrated care services, and member experience quality. The most verifiable gap is reimbursement turnaround — Alan processes more than 70% of reimbursements in under one hour and 99% within 24 hours, compared to 3–5 business days cited for MGEN and 2–4 days for most traditional mutuelles. Alan's consumer NPS of 70+ significantly exceeds what independent review platforms record for Malakoff Humanis (84% satisfaction on a binary scale), Harmonie, and AG2R. Alan's 100% digital model — no physical branches, no inbound telephone line for standard queries — is both its source of cost efficiency and the most commonly cited limitation in consumer reviews, particularly for less digitally literate members or those with complex care needs. In pricing, Alan's 2026 individual plans are: Green (€39–55/month for entry-level), Blue (€59–79/month for mid-coverage), and Purple (€89–120/month for premium). Alan also offers employer group plans (Green, Blue, Zen) where the employer must cover at least 50% per ANI law. Alan raised its premiums approximately 7% on average in 2026 to reflect 9.5% medical inflation. Harmonie Mutuelle enterprise pricing is estimated at €15–80/month per employee depending on tier, company demographics, and convention collective. AG2R Flexéosanté starts at €19.77/month for SMEs. MGEN's base PSC premium is €75.40/month gross (€37.70 for employee with 50% employer share). Pricing differences between Alan and comparable incumbents are within roughly ±15–20% for equivalent coverage tiers; neither side has a structural cost advantage large enough to make price the primary switching decision. Alan charges a 12–14% platform subscription fee on top of insurance premiums for its health platform services — a pricing model unique among French CHI players. This secondary revenue stream helps diversify monetisation beyond pure insurance underwriting but creates an additional cost line that budget-sensitive employers may scrutinise. Switching friction for employer group contracts is primarily calendar-based: French CHI contracts renew annually, and notice periods typically run 1–2 months before renewal. Alan imposes no switching fee for onboarding, and its digital onboarding eliminates paperwork. However, prior-provider notice periods still apply, and PSC and CCN-bound sectoral agreements can lock in specific incumbent providers for the duration of the CCN designation. For SMEs and tech companies — Alan's core market — multi-homing is relatively easy and switching effort is genuinely lower than with paper-heavy traditional processes. [CP026, CP027, CP028, CP029, CP030, CP031]

3.5 Moat Durability, Commoditisation Risk, and Adverse Evidence

Alan's competitive moat rests on five reinforcing factors. First, its ACPR regulatory standing as the first new independent health insurer licensed in France since the 1980s provides a legal foundation that no digital broker or care-platform can replicate quickly. Second, its technology infrastructure — automated claims, a fully integrated care app, and AI tools including the Mo health assistant — gives processing speed and user experience that incumbents have not matched. Third, its data flywheel of 73M+ reimbursements and 5.9M+ consultations creates a training corpus and actuarial precision advantage that grows with each member year. Fourth, its brand equity, reflected in NPS 70+ and 90% member satisfaction, supports retention and reduces involuntary churn. Fifth, enterprise lock-in deepens as companies integrate Alan's HR portal, wellness modules (Alan Mind, Alan Kids, Alan Clear), and AI health guidance into their benefits stack. Key durability risks: (1) Incumbent digitisation catch-up — AXA, Malakoff Humanis, and Harmonie Mutuelle are investing in employer digital portals and wellbeing add-ons; if they close the UX gap within three to five years, Alan's experiential moat narrows significantly. (2) Group-level unprofitability — net losses of €26M in 2025 (down from €56M in 2024) mean Alan remains reliant on external capital; group break-even is targeted for 2027 but depends on international scaling in Belgium, Spain, and Canada. (3) Distribution gap — Alan's direct digital-only channel cannot match the broker networks, CCN mandatory agreements, and PSC tender wins that incumbents leverage. (4) Commoditisation of digital UX — as incumbent portals improve and competing insurtechs replicate basic app features, the experiential gap will compress. Adverse evidence: Analyst Matteo Carbone (IoT Insurance Observatory) stated that Alan's €4B valuation is "unrealistic" for a company with approximately half a billion in premiums that is not yet profitable, qualifying this only with the distribution value unlocked by Belfius's equity stake. This skepticism — from an independent insurtech analyst, not a competitor — underscores that the current valuation embeds significant execution risk. A growth or profitability disappointment could materially reprice the competitive narrative. [CP040, CP041, CP042, CP043, CP047, CP048]

3.6 Exhibits

4.1 Revenue Model and ARR Trajectory

Alan's business model rests on two explicitly distinct revenue layers. The first is insurance premiums, priced at near-equilibrium with expected claims—Alan targets a claims-to-premiums ratio of approximately 100%, meaning premiums are largely passed through to reimbursements with minimal net actuarial margin for Alan. The second is a per-member monthly subscription fee that funds the digital health platform: AI-powered medical chat, optical ordering, back-pain programs, and prevention tools. The CEO stated publicly that the management fee is set at "12 to 14% of premiums," making the subscription layer a structurally separate, high-margin SaaS-like stream atop a low-margin insurance base. Prévoyance (disability/life) represents approximately 25% of French revenue and follows the same pass-through structure. ARR grew from €340M (FY2023) to €505M (FY2024, +48%) to €785M (FY2025, +53%), with Q1 2026 at €804M, on track toward the €1B annual target. France accounts for more than three-quarters of group ARR. The public sector, following wins at the Ministry of Economy and Finance (135,000 civil servants) and earlier government ministries, represented 32% of FY2024 net ARR growth and multiplied fourfold in FY2025. International markets (Belgium, Spain, Canada) are growing but remain a minority of group revenue. The implied subscription revenue at 12–14% of €785M is approximately €94–110M, which constitutes the primary economic profit pool from which operating expenses must be recovered before any group net result can turn positive. [CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Cost Structure, Unit Economics, and Loss Trajectory

Alan's operating costs fall into three main buckets: technology and AI investment, sales and marketing, and general and administrative overhead. Headcount grew from ~550 employees (start of FY2024) to ~600 (end FY2024, +8%) to approximately 800 (FY2025, +10% payroll growth disclosed by CFO Mihaela Albu in March 2026). Revenue per employee reached an estimated €981K/employee in FY2025 (€785M / 800), reflecting significant operating leverage—each Alaner generates roughly twice the revenue as in FY2023. The net loss trajectory improved substantially: from ~€59–61M (FY2023, per press) to ~€54M (FY2024, per press-release preliminary) to €26M (FY2025, per SFCR). A material discrepancy exists between the press-released FY2024 loss figures (~€54M cited in January 2025 press conferences and the Maddyness/Obliginfos press) and the SFCR-published figure (-€34M for FY2024), resolved to -€26M in FY2025. This gap likely reflects differences in Solvency II accounting versus full-group corporate P&L. France achieved operational profitability in FY2025—a structurally important milestone because France is >75% of group revenue. The loss ratio (claims-to-premiums) targeting ~100% is management-stated but never independently verified; any persistent adverse deviation would erode the subscription margin and accelerate cash consumption. The implied "true gross margin" on the subscription layer is very high (software-like) but the consolidated gross margin including pass-through premiums is much lower. Losses as a share of ARR fell from ~17% in FY2023 to ~3.3% in FY2025, a compelling improvement in revenue quality. [CI010, CI011, CI012, CI013, CI014, CI015]

4.3 Capital Adequacy and Solvency II Compliance

Alan is regulated as an insurance group under Solvency II (Directive 2009/138/EC), supervised by the ACPR (Autorité de Contrôle Prudentiel et de Résolution). Under Solvency II Pillar I, Alan must hold eligible own funds at or above its Solvency Capital Requirement (SCR)—the amount of capital needed to absorb losses with 99.5% probability over one year. Alan's SCR is approximately €105M, driven primarily by health insurance underwriting risk (exposure to healthcare cost fluctuations and prévoyance commitments). Alan holds regulatory own funds exceeding €374M, a coverage ratio of more than 3.6× the SCR. The FY2023 SFCR cited an approximate solvency ratio of 450%, versus the French complementary health insurance market average of 241% (H1 2025 per ACPR/Chambers data) and the regulatory minimum of 100%. In FY2025, own funds increased by €80M versus end-FY2024, partially from improved net result and capital structure management. Cash and liquid deposits total approximately €376M (end FY2025), held conservatively in deposit accounts with tier-one financial institutions—no investments in public equities or high-risk instruments, consistent with regulatory capital preservation policy. Alan's reinsurance program involves Swiss Re, GenRe, CNP Assurances, Hannover Re, and Belfius Insurance, providing structured risk transfer to cap healthcare cost volatility and protect the SCR from adverse claims development. The €100M March 2026 capital raise was characterized by CFO Albu as "opportunistic"—the company had no immediate capital need (with €376M on hand at end FY2025)—and is intended to fund M&A and international expansion rather than cover operational shortfalls. Annual SFCR publication is a mandatory Solvency II obligation; Alan's FY2025 SFCR was validated by the board of directors on 22 April 2026. [CI019, CI020, CI021, CI022, CI023, CI024]

4.4 Public Financial Gaps and Diligence Verdict

Alan's public financial disclosure is limited to: SFCR summary web pages (not a full PDF SFCR in accessible form), ARR and net loss figures disclosed at press conferences, and solvency ratio ranges cited in corporate communications. No GAAP or IFRS audited consolidated financial statements are publicly available. The absence of a statutory audit trail for the full group means investors and diligence parties cannot independently verify revenue recognition, balance sheet items, or cash flow dynamics. Specific gaps include: (1) the exact claims-to-premiums (loss) ratio—a core health insurance metric—has never been disclosed, leaving actuarial risk unquantifiable; (2) customer acquisition cost and payback period are completely private, preventing standard SaaS unit-economic benchmarking; (3) per-country P&L (France, Belgium, Spain, Canada) is unavailable, masking the drag from international scale-up markets on the path to group profitability; (4) subscription fee levels per member by plan tier are not officially disclosed; third-party comparators cite €39–120/month in total plan premiums but subscription vs. insurance premium splits within each tier are opaque. Adverse concerns raised by French trade unions and the MGEFI (incumbent mutuelle at the French Ministry of Finance) center on Alan's ongoing losses and ability to honor multi-year public sector obligations. Analyst Matteo Carbone (IoT Insurance Observatory) called Alan's €4B valuation "unrealistic" relative to premiums and lack of profitability. These concerns are partially mitigated by Alan's Solvency II capital buffer (3.6× SCR), ACPR supervision, and reinsurance program. The financial verdict is that Alan demonstrates strong revenue quality improvement and a credible path to group profitability by 2027, but multiple critical private metrics prevent a fully underwritten financial assessment without a data room. [CI028, CI029, CI030, CI031, CI032, CI033]

4.5 Exhibits

5.1 Product Portfolio & Digital App Experience

Alan's product portfolio has expanded into a comprehensive health super-app that integrates digital insurance, medical care, prevention, and commerce in a single mobile experience. At its core, the Alan app (4.9/5 App Store rating, version 1.451.0 as of May 2026) gives members instant access to a digital Tiers Payant card for direct billing at pharmacies and healthcare providers, photo-based insurance claim submission, and real-time reimbursement notifications. The app serves as the entry point for all other Alan products: Alan Clinic (medical chat and video consultations 7 days per week), Alan Play (gamified health challenges and prevention programs), Alan Précision (precision biomarker testing via the Aro acquisition), and Alan Shop (curated wellness commerce including optics). Fifty percent of reimbursements are processed in under five minutes—a benchmark that sets Alan apart from traditional insurers that routinely require 48–72 hours. Members submit claims by photographing receipts within the app; AI autoparsing handles document extraction without requiring typed input. The HR administration portal automates employee enrollment and coverage lifecycle via HRIS integrations, reducing insurance administration to fewer than two hours per year for the average SMB. Alan operates through six distinct legal entities—Alan Insurance, Alan Services, Alan Tech, Alan CA (Canada), Marmot BE (Belgium), and Marmot Iberia (Spain)—each locally regulated and serving a distinct market, providing jurisdictional separation for compliance and data residency. [CE001, CE002, CE003, CE037, CE038, CE039]

5.2 Alan Clinic, Mo AI Assistant & Mental Health

Alan's flagship clinical product is Alan Clinic, a 7-days-a-week medical consultation platform that combines licensed physicians with Mo, an AI-powered medical assistant. As of Q1 2026, Mo is deployed to more than 500,000 members in France, delivering four times the member engagement of Alan's prior human-only Clinic model. Mo's design is fundamentally hybrid: the AI generates an instant response to member health queries, but every conversation is reviewed and validated by a board-certified physician within 15 minutes. This architecture allows physicians to supervise multiple AI conversations simultaneously, enabling a consultation volume— 260,000 medical chats equivalent to doctor visits in one reporting period—that would be economically impossible with pure physician headcount. Alan's large-scale clinical study, described as the first of its kind for conversational medical AI in real settings, enrolled 1,566 member conversations over three weeks. Of 926 eligible participants initially offered a human doctor, 81% chose Mo. Post-conversation patient satisfaction was 4.6/5, and 95% of supervising physicians rated Mo's responses as good or excellent. Mo drives approximately 30% of all teleconsultation traffic within the Alan ecosystem and has automated 40% of care conversations company-wide as of Q1 2026. Alan Mind (mental health) extends Clinic into psychological support, with AI-powered journaling adopted by an estimated 14% of members and on-demand access to licensed psychologists. [CE004, CE005, CE006, CE007, CE008, CE009]

5.3 Technology Architecture & AI-Driven Operations

Alan's engineering foundation is built on Python/Flask backend services, React and React Native frontends, and PostgreSQL in a shared monorepo—a stack optimised for rapid iteration and end-to-end team ownership under a "you build it, you own it" engineering culture. All alan.com services are hosted on Amazon Web Services (AWS) Europe, with daily deployment cadences. Alan's careers pages confirm distributed team ownership where any engineer can take a feature from conception to production without handoff bottlenecks. AI is embedded throughout the operating model rather than isolated as a product feature. The fraud detection AI prevented €1 million in fraudulent claims in Q4 2024 alone. Claims document autoparsing reaches 67% of submitted claims in France and 39% in Belgium, materially reducing manual review labour. AI-powered customer support auto-resolves 17.5% of all mobile contacts (up from 9% in H1 2024), allowing customer service headcount to remain flat as membership scales. The most distinctive internal AI deployment is Hopper, Alan's autonomous coding agent, which enables non-engineer employees to submit production pull requests; pull requests per engineer increased 20–30% in Q1 2026. HR platform integrations—Payfit, Workday, and Peepel—automate employer enrollment and coverage lifecycle management without manual configuration. [CE020, CE021, CE025, CE026, CE027, CE028]

5.4 Prevention, Gamification & Alan Précision

Alan's prevention portfolio spans four offerings: Alan Play (gamified physical activity via step challenges), Alan Mind (mental health journaling and psychologist access), Alan Back Pain Program (structured physiotherapy coaching), and Alan Précision (precision preventive health via biomarker testing). Alan Walk, the flagship gamification product, tracks daily activity through the app and rewards members with berries—a virtual currency exchangeable for Alan Shop discounts or charitable donations. By Q4 2024, Alan Walk had enrolled 20,000 members across 900 companies, achieving 35% weekly active users and 35% retention at six months. Highly engaged users show an approximately 1,200-step (27%) daily increase compared to baseline—a figure Alan notes is from a self-selected high-engagement cohort. Alan Shop reached 17% contact lens market share and 9% glasses market share among French members. The Back Pain Program serves more than 22,000 members, with Alan claiming an 87% meaningful-pain-relief rate within 14 days in company-reported outcomes; no independent randomised controlled trial has been published. The highest-potential new asset is Alan Précision, launched in March 2026 following Alan's acquisition of Aro. Précision analyzes 80+ biomarkers via twice-yearly blood tests and generates physician-supervised personalised action plans. It integrates longitudinally with Mo, Alan Clinic, Play, and Shop. The 1,500+ waitlist was accumulated with zero marketing spend. Prévenir, Alan's occupational health arm, now covers 14,000 employees across 100 companies, including an on-site medical centre at Alan's Paris headquarters. [CE014, CE015, CE016, CE017, CE018, CE019]

5.5 Trust, Compliance & Data Security

Alan holds ISO 27001 certification—audited and certified by SGS—covering 100% of its teams, operations, and geographies (France, Belgium, Spain, and Canada). The company's CNIL data processing declaration (No. 2004097 v0) governs automated health data handling under French and EU law. Alan's February 2026 privacy policy commits explicitly to never selling member data and never using health data for differential pricing, a meaningful trust differentiator relative to most traditional insurers. The structural security risk is material. Alan delegates third-party payment processing to Almerys, which suffered a breach in early 2024 affecting more than 33 million French policyholders; CNIL launched a formal investigation. On 23 May 2026—the date of this report—Le Figaro confirmed a new Almerys cyberattack affecting Alan members, with social security numbers and insurance contract numbers exposed. Banking data and health data were not compromised. Alan immediately shut down the affected platform, notified CNIL and ACPR, and committed to individually notifying affected members via email. Independent review aggregators (Selectra, Trustpilot) show a consistent adverse pattern: members report difficulty reaching human advisors, unexpected premium increases, and AI chatbot misclassification of their queries as out of scope. These complaints are structurally connected to Alan's digital-first, AI-heavy service model and represent an ongoing churn risk in segments that value human accessibility above speed and convenience. [CE022, CE023, CE024, CE040, CE042, CE043]

5.6 Roadmap & Product Evolution

Alan's 2026 roadmap reflects two strategic bets: extending AI from the product layer into go-to-market and internal operations, and rebuilding the technology stack into a global multi-country architecture that enables 10× faster entry into new geographies. On the commercial AI front, sales productivity gains from AI assistance are expected to reach approximately 30% in 2026, building on the ~50% improvement cited by Alan's chief revenue officer at the January 2025 results press conference. Alan has also previewed a medium-term ambition of a "single AI sales rep" managing a full deal cycle by 2027. The multi-country architecture rebuild—confirmed in the Q1 2026 shareholder letter—represents the engineering prerequisite for expansion beyond the current four markets (France, Belgium, Spain, Canada). Alan Précision, Prévenir, and the planned extension of Mo to Belgium and Spain are the near-term product releases most likely to shift Alan's product-market fit outside its French core. The Hopper coding agent is expected to increase autonomous code contributions further, narrowing the competitive moat between Alan's staffing cost structure and larger incumbents. [CE034, CE035]

5.7 Exhibits

6.1 Customer Base & Segmentation

Alan's customer base spans two primary commercial channels: business-to-business (B2B) employer-sponsored group health insurance, which drives the large majority of its 1.1 million members, and a smaller but growing business-to-consumer (B2C) segment for self-employed professionals (travailleurs non-salariés, TNS) and individual members. In France, the SME segment (1–500 employees) remains the historical core; Alan entered the market targeting tech startups before scaling to broader mid-market employers. Individual and TNS plans (Rubis, Emeraude, Saphir/Diamant) are priced at €49–91/month for a 40-year-old profile, positioning Alan at the premium end of the individual market. Geographically, France dominates member count and is Alan's only operationally profitable market as of 2025. Belgium and Spain are meaningful secondary markets where HP and Volkswagen are cited as named enterprise clients, with Belgian distribution further accelerated by the Belfius bank partnership. Canada obtained provincial licences in 2024 and has commenced commercial operations, though it remains early-stage. Public-sector exposure has risen materially since 2023. Alan won the Assemblée nationale contract in 2023, the Ministry of Ecology (60,000 civil servants) and Prime Minister Services (4,900 employees) in 2024, and the Ministry of Finance (Bercy, 130,000 civil servants, live January 2026) in 2025. This extends Alan's buyer profile from private employers to central-government HR departments, introducing different procurement dynamics, longer contract cycles, and structural renewal risk tied to French PSC reform continuity. [CU001, CU004, CU009, CU010, CU031, CU034]

6.2 Adoption & Growth Trajectory

Alan's member count grew from approximately 650,000 (mid-2024 per OTPP profile) to 1.1 million by Q1 2026, nearly doubling in roughly 18 months. Concurrently, covered companies expanded from ~25,000 to 37,000+. The step-change in member growth was partly driven by large block contracts: the Ministry of Finance alone contributed 130,000 direct civil servants from January 2026, with a 96% affiliation rate — the single most visible retention proxy for a discrete cohort. The Q1 2026 shareholder letter confirms new business acquisition grew 60% year-on-year with similar marketing investment, pointing to materially improved sales and marketing productivity. Revenue trajectory corroborates member growth: ARR rose from €505M (mid-2024) to €785M (end-2025) and €804M (Q1 2026), representing approximately 59% annual growth. The partial dilution of per-member revenue from lower-premium public-sector contracts is an inference based on the relative ARR-to-member growth rates, not publicly disclosed. Operational metrics released in the press room show 99% of reimbursements processed within a day and 73 million+ reimbursements processed since 2016 as evidence of platform maturity. Product adoption beyond core insurance is accelerating: Mo AI health companion is live for 500,000+ members in France (roughly 45% of French members), delivering four times the engagement of the prior human-powered Clinic. Prévenir (occupational health) covers 14,000 employees across 100 companies, showing upsell traction into workplace prevention. Alan Play step challenges drove a reported +70% lift in daily active users during team events. [CU002, CU003, CU007, CU008, CU011, CU013]

6.3 Named Customer Proof

Alan's named customer evidence is strongest in the French public sector, where competitive tender outcomes and official ministry announcements provide primary-tier corroboration. The Ministry of Finance (Bercy) contract is the most extensively documented: Alan's official blog post, multiple independent news outlets, and the Q1 2026 shareholder letter all confirm the 130,000-agent onboarding with a 96% affiliation rate. The Ministry stated Alan's offer was "mieux-disante" on economics, service quality, and lowest management costs. The Ministry of Ecology (60,000 agents) and PM Services (4,900 employees) contracts in 2024, and the Assemblée nationale contract in 2023, establish a documented staircase of public-sector wins. In total, Alan has at least tripled its public-sector coverage base within 24 months. In the private sector, HP and Volkswagen are the only named enterprise employer clients confirmed via press coverage (abcmoney.co.uk, fintech.global). Alan does not publish a customer list, and specific deployment sizes or outcome data for these clients are not publicly available. OTPP's investor profile provides independent corroboration that Alan "partnered with 25,000 companies" at an earlier stage. The Activepieces case study documents Alan's internal use of automation technology — useful as a technology-vendor reference rather than a health-insurance customer proof point. Aggregate customer review scores (4.0–4.2/5 across 2,300+ verified reviews on Goodassur aggregating Opinion Assurances, Trustpilot, Google Reviews, and Selectra) and the Ministry of Finance's official evaluation together represent the strongest third-party endorsements. Adverse reviews from Opinion Assurances document reimbursement errors, difficulties reaching a human advisor, and premium increases as recurring friction points, particularly for complex claims and TNS profiles. [CU005, CU006, CU012, CU014, CU015, CU016]

6.4 Retention, Satisfaction & Durability

Alan does not publicly disclose net revenue retention (NRR), gross revenue retention (GRR), or cohort-level churn rates. Available proxies are: a self-reported 90% member satisfaction rate, an NPS of 68 versus an industry average of approximately 3 (cited in the official Bercy announcement blog), and an aggregate consumer review score of 4.0–4.2/5 across ~2,300 verified reviews as of May 2026. The 96% affiliation rate at Ministry of Finance onboarding is a credible activation proxy for a single large cohort, though activation differs from annual renewal rate. For employer-sponsored B2B health insurance broadly, industry benchmarks suggest 85–92% annual retention when employers bear the majority of the premium. Alan's specific retention by segment is unknown. ARR growth from €505M to €804M over ~18 months implies strong portfolio-level revenue retention, but does not isolate individual employer renewal rates or segment mix effects. The France market's operational profitability implies positive unit economics at scale, which is an indirect indicator of durable retention rather than high churn. Adverse review signals on Opinion Assurances and Goodassur identify recurring friction in three areas: reimbursement errors and laborious correction processes, absence of direct phone support for complex cases, and premium increases perceived above market average for TNS and individual customers. The Selectra platform shows a notably low 1.5/5 from only 10 reviews — illustrating platform-level selection bias — while Google Reviews (4.2/5, 1,464 reviews) and Trustpilot (4.1/5, 160 reviews) are consistently more positive, indicating that satisfied employer-covered employees dominate high-volume review channels. [CU024, CU025, CU030, CU032, CU035, CU040]

6.5 Concentration & Expansion Risk

Alan's most material concentration risk is its rising public-sector exposure. The PSC contracts won across 2023–2026 (Assemblée nationale, Ministry of Ecology, PM Services, Ministry of Finance) collectively represent a large bloc of covered lives under a single procurement regime. While each ministry is a separate contract, they all derive from the PSC reform mechanism. If a future French government reverses PSC reform, or if Alan fails to renew tenders at cycle end, a material share of its member base could exit in a compressed timeframe. Execution risk on the Bercy contract is active: MGEFI (a Matmut subsidiary), the incumbent insurer, filed a pre-contractual legal challenge in June 2025 after being displaced. An earlier MGEN challenge against Alan's Ministry of Ecology win was dismissed at referé stage, providing a precedent against reversal, but the MGEFI challenge outcome was unresolved as of the run date. French MP Philippe Latombe has publicly flagged Alan's AWS hosting of civil servant health data as a digital sovereignty concern — a regulatory exposure that could affect future PSC tender eligibility. On channel concentration, Belgium relies substantially on the Belfius bank distribution partnership for employer acquisition. Canada is too early in its growth arc to carry meaningful concentration risk. Offsetting these risks: the 37,000-company private-sector portfolio is highly diversified across SME sizes and industries, and no single private employer is disclosed as representing a material revenue concentration. Public-sector contracts, while large in covered lives, are priced at lower per-member premiums, so their revenue concentration impact is less severe than their headcount concentration. [CU026, CU027, CU028, CU029, CU036, CU037]

6.6 Exhibits

7.1 Regulatory and Legal Risk Landscape

Alan Insurance SA operates as a licensed health and provident insurer under the supervision of France's Autorité de contrôle prudentiel et de résolution (ACPR), bound by the full Solvency II framework. Alan's own 2024 SFCR discloses €294 million in own funds covering the Solvency Capital Requirement 4.6 times and the Minimum Capital Requirement more than 18 times—comfortably above the sector minimum. However, the revised Solvency II directive now applies across EU member states from 2026, introducing eight technical recalibrations—including new yield-curve extrapolation methods, revised rate-shock factors, and a reformulated Volatility Adjustment—that Alan must model to confirm its capital adequacy position does not deteriorate under the new standard-formula parameters. The ACPR's published 2026 work programme identifies regulatory simplification, governance, AI supervision, and DORA implementation as its five priority axes. Particular pressure falls on Axis 3 (DORA cyber/operational resilience) and Axis 4 (AI risk supervision), both of which bear directly on Alan's technology-centric model. In the public-procurement arena, Alan's Bercy contract for 130,000 civil servants launched on 1 January 2026 after the displaced mutual MGEFI filed a référé précontractuel; the Tribunal administratif de Paris rejected this injunction on 20 June 2025 (ordonnance #2514913/4-1), validating the procurement procedure. MGEFI has signalled intent to pursue a merits challenge on the substance of the award, which leaves a non-trivial litigation tail risk. Trade unions representing the seven Bercy unions publicly opposed the transition, citing data-sovereignty and service-quality concerns, adding political complexity to contract continuity. Finally, the EU AI Act classifies health-insurance underwriting algorithms as high-risk AI systems; compliance obligations for Alan's MO AI system and any claims-scoring algorithms activate on 2 August 2026, with penalties reaching €15 million or 3% of global annual turnover. [CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Cybersecurity and Data Privacy Risks

Alan's most material operational risk is its structural dependence on Almerys, the third-party tiers-payant operator that processes all health-reimbursement transactions. Almerys has been compromised twice in 24 months: a January 2024 attack exposed data on 33 million French insured persons (the CNIL opened a formal investigation); and a second attack in May 2026—confirmed on the run-date of this report—again exposed Alan member records including names, birth dates, social-security numbers, member numbers, and coverage details. An estimated 15.5 million unique social-security numbers appeared in the file offered for sale; because one social-security number links to multiple family members, the total individuals at risk is substantially higher. Alan confirmed that banking data, health-treatment details, passwords, and contact information were not compromised in 2026, and that no intrusion reached Alan's own servers. However, the ACPR and CNIL were immediately notified and investigations are open. This is not a one-off event: Almerys is a shared infrastructure dependency for Alan, MGEN, Harmonie Mutuelle, and AG2R La Mondiale, making Alan a systematic indirect beneficiary—and indirect hostage—of that operator's security posture. Separately, Alan hosts all member health data on Amazon Web Services (AWS), whose EU data centres hold HDS (Hébergeur de Données de Santé) certification. Yet AWS remains subject to US extraterritorial legal instruments (Cloud Act, FISA Section 702), which prompted French parliamentarian Philippe Latombe to file question QANR5L17QE7230 asking whether the government would require Alan to migrate to a SecNumCloud-certified sovereign provider. France's concurrent exclusion of AWS, Microsoft Azure, and Google from the national Health Data Hub tender further signals a tightening political consensus on data sovereignty that could eventually mandate a costly platform migration for Alan's public-sector contracts. [CR013, CR014, CR015, CR016, CR017, CR018]

7.3 Partner and Dependency Risks

Alan's risk transfer programme relies on a concentrated panel of reinsurance partners. For French health business, Alan Insurance cedes 49% of net premium to Swiss Re, GenRe, and CNP Assurances under a 50% nominal quota-share arrangement. Prévoyance (disability, life) risk is reinsured at 80% with Hannover Re from 2025, supplemented by a GenRe excess-of-loss treaty for extreme arrêt-de-travail scenarios. Belgian health is ceded at 60% jointly to Swiss Re and Belfius Insurance, whose parent Belfius Bank is also a strategic investor in Alan. This Belfius dual role—reinsurer and investor—creates a conflict-of-interest dimension to monitor: a deterioration in Belfius's own financial position or a strategic shift could simultaneously impair both Alan's capital base and its Belgian reinsurance programme. The SFCR 2024 discloses that counterparty risk (reinsurer and banking-partner credit risk) is the second-largest SCR component at €19.6 million (24.5% before diversification), reflecting the materiality of this dependency. Reinsurance cost in 2024 was net negative at −€1.8 million, indicating a drag during a growth phase when risk-transfer costs are front-loaded relative to maturing claim-experience credits. On the technology-infrastructure side, the AWS dependency noted in the cyber section extends to operations broadly: Alan's entire platform—claims management, member app, tiers-payant connectivity, and AI systems—runs on AWS infrastructure. An AWS region outage or a legal challenge under French data-localisation policy would simultaneously affect all geographies and all product lines. Alan has ISO 27001 certification and conducts penetration tests, but DORA now mandates a documented exit plan for every critical ICT third-party provider, placing the Almerys and AWS dependencies under formal regulatory scrutiny. [CR023, CR024, CR025, CR026, CR027, CR028]

7.4 Operational and Execution Risks

Alan's digital-only service model—no telephone line, all support via in-app chat—is a structural vulnerability for complex claims. Customer reviews on platforms including Goodassur, Opinion Assurances, and Selectra consistently surface frustration with maternity reimbursements, inconsistent partial-coverage decisions, and delays when cases fall outside standard automation pathways. These reviews represent adverse sentiment that predates and supplements the data-breach risk. Health-cost inflation was flagged in Alan's own SFCR 2024 as a factor that exceeded actuarial forecasts in 2024, adversely affecting technical equilibrium. This underwriting risk is partly mitigated through annual repricing rights and quota-share reinsurance, but rapid member growth (686,000 at end-2024; 1,059,000 at end-2025) raises the absolute stakes of any tariff misjudgement. Geographic concentration remains high: France accounted for 87% of insured at end-2024, and the public-sector segment—while strategically important—introduces a new customer-concentration risk if a single large contract (like Bercy's 130,000 agents) is repriced, not renewed, or politically disrupted. The SFCR identifies operational SCR at €8.9 million (11.2%), driven by system-failure and fraud risk in the company's highly automated, high-volume transaction processing environment. Alan's international expansion into Canada, Belgium, and Spain creates simultaneous multi-regulatory compliance pressure: different solvency frameworks, distinct data-protection regimes, varying procurement rules, and local talent demands. The company is majority-France staffed and culture-intensive (radical transparency culture documented in the SFCR), which may create friction as it scales geographically. The EU AI Act's August 2026 deadline for high-risk AI systems—specifically applicable to any underwriting or claims-scoring algorithm that influences coverage decisions for natural persons—adds a compliance burden that requires conformity assessments, bias-testing infrastructure, and technical documentation not normally part of an insurer's product-development workflow. [CR029, CR030, CR031, CR032, CR036, CR037]

7.5 Mitigations, Kill Criteria, and Diligence Asks

Alan has built meaningful first-generation mitigations against its key risks. Solvency II coverage at 4.6× SCR and 18× MCR provides a substantial capital buffer; the company maintains liquidity almost entirely in short-duration cash deposits at tier-1 banking partners, minimising market and liquidity risk. Reinsurance diversification across five counterparties (Swiss Re, GenRe, CNP, Hannover Re, Belfius Insurance) reduces single-counterparty default risk even if credit concentration in the Swiss Re/GenRe panel warrants monitoring. ISO 27001 certification and regular penetration testing demonstrate a baseline security posture above French insurance norms, though the Almerys breach exposures reveal the limits of perimeter security when critical dependencies are shared infrastructure. The ACPR and CNIL notification workflows triggered promptly after both Almerys breaches, and Alan's public communications were rapid and transparent, limiting acute reputational damage. On the procurement litigation front, the Tribunal administratif rejection of the MGEFI injunction reduced near-term contract risk, though the merits case creates an ongoing overhang. Investors should define clear tripwires for thesis-break scenarios: a CNIL formal sanction or fine exceeding €5 million; ACPR mandatory capital add-on under Pillar 2; MGEFI merits-case success reversing Bercy contract; forced SecNumCloud migration costing more than €50 million; EU AI Act non-compliance enforcement action before August 2026 rectification; or net loss for 2026 (group-wide) at a rate above 5% of ARR, signalling that the France profitability milestone is reversing rather than consolidating at scale. [CR040, CR043, CR046, CR047, CR048]

7.6 Exhibits

8.1 Funding History and Current Valuation Mark

Alan's valuation arc is one of the most compressed and consistent in European insurtech. Starting from a seed round of €12M in October 2016, the company progressed through seven further rounds to reach a post-money valuation of €5B in March 2026—a total equity capital raise of approximately €754M. The Series F in September 2024 set the €4B mark at a €173M raise led by Belgian bank and insurer Belfius, which simultaneously entered a distribution partnership giving Alan access to Belfius's corporate and institutional clients. The March 2026 follow-on raised €100M led by Index Ventures (existing), with new institutional backers Greenoaks, Kaaf, and SH Capital and angel investors including Shopify founder Tobi Lütke and footballer Antoine Griezmann. The valuation step-up of 25%—from €4B to €5B—was achieved despite Alan still reporting a group net loss of €26M in FY2025, albeit sharply improved from €34M in FY2024. The €5B mark reflects a €804M Q1 2026 ARR run-rate (implying approximately 6.2× forward ARR) and a disclosed path to group profitability by 2027. Critically, 30% of European unicorns lost their billion-dollar status in 2024–2025, and Alan's upward revaluation marks it as a clear outlier in a period of multiple compression across the region. The ACPR confirmed Alan's FY2025 Solvency and Financial Condition Report (SFCR) was board-approved on 22 April 2026; Alan holds regulatory capital of more than €374M against a Solvency Capital Requirement of approximately €105M (3.6× coverage vs. the French market average of 2.41×). The €100M March 2026 round was described by CFO Mihaela Albu as "opportunistic," given the existing €376M cash reserve—indicating no near-term solvency or liquidity need, and framing the raise as M&A dry powder and growth capital rather than survival financing. Founders and employees retain approximately 40% of the capital and the majority of voting rights, which limits secondary liquidity for early investors and means any near-term IPO would be a founder-controlled decision. [CV001, CV002, CV003, CV004, CV005, CV006]

8.2 Valuation Methodology and Comparable Analysis

Alan operates as a hybrid: a regulated Solvency II insurance carrier whose primary economic profit pool is a SaaS-like management fee of approximately 12–14% of premiums, layered atop a near-zero-margin premium pass-through. This dual-layer structure creates a valuation ambiguity: should Alan be priced as a carrier (1.5–3.5× net revenue), a tech-enabled MGA (3–8× net revenue), or an AI-native insurer (15–30× net revenue)? The answer has material consequences. At €5B valuation and €785M FY2025 ARR, Alan's ARR multiple is approximately 6.4×—in the upper band for tech-enabled carriers but well below the SaaS-premium tier. If valued solely on its subscription revenue (12–14% of €785M = approximately €94–110M), the implied multiple rises to approximately 46–53× net subscription revenue, a figure structurally impossible to support. The appropriate framing is the blended ARR multiple (6.4×), acknowledging that premiums and subscriptions are co-bundled and cannot be disaggregated for multiple purposes. The Windsor Drake Q1 2026 Insurtech Valuation Report confirms that public insurtechs currently trade in the 6–10× range while private markets can award higher premiums for quality and growth. Nelson Advisors' European HealthTech M&A 2025 report puts average HealthTech revenue multiples at 4.8× (Q1 2025), rising to 6–8× for AI, telehealth, and analytics platforms. On this view, Alan's 6.4× blended multiple is at the high end of the European HealthTech M&A market but not an outlier, assuming the AI/tech positioning premium is substantiated. Comparing to public comparables: Oscar Health (OSCR, NYSE) has a TTM revenue of $13.3B and market cap of $6.83B (P/S ≈ 0.51×), but Oscar is a full-stack carrier with very different revenue composition and operating at a scale 17× Alan's ARR. Lemonade (LMND, NYSE), a technology-first insurer with $844.7M TTM revenue, trades at a P/S of approximately 5.14× and EV of $4.17B—a more comparable scale, though Lemonade remains loss-making (net loss $138.9M TTM). Clover Health (CLOV, NASDAQ) has an EV of approximately $2B on $2B LTM revenue (EV/Revenue ≈ 1×), trading closer to a pure carrier. The public-market precedent suggests that the private premium Alan commands (6.4× ARR) reflects both illiquidity and growth premium over public comps. Key structural disadvantages vs. public peers: no GAAP/IFRS audited consolidated accounts, no disclosed loss ratio, and no per-country P&L—all of which would be required for any public market listing and significantly elevate diligence risk. [CV013, CV014, CV015, CV016, CV017, CV018]

8.3 Investment Thesis and Anti-Thesis

The investment thesis for Alan rests on five interlocking pillars. First, market position: Alan is the dominant new-entrant insurer in the €47B French complementary health market, having become the first ACPR-licensed carrier since the 1980s and growing to 1.059M members with less than 1% aggregate market share—implying a multi-decade runway before hitting saturation. Second, revenue quality: ARR has compounded at approximately 50% per year for three consecutive years (€340M → €505M → €785M), with each cohort of members generating recurring subscription fee revenue structurally decoupled from claims volatility. Third, financial trajectory: France achieved operational profitability in FY2025, losses as a share of ARR fell from approximately 17% in FY2023 to 3.3% in FY2025, and the March 2026 cash raise was explicitly described as opportunistic (not survival capital). Fourth, AI moat: Alan's Mo AI health assistant, automated reimbursement processing (70% within one hour), and fraud detection capabilities create operational leverage that is difficult for incumbents using legacy systems to replicate. Fifth, capital discipline under regulation: a 3.6× Solvency II coverage ratio and entirely cash-deposit asset allocation (no equity or structured product exposure) signal conservative risk management aligned with supervisory expectations. The anti-thesis is equally coherent. First, the Solvency II capital constraint: because Alan must hold regulatory capital above its SCR as a condition of its licence, the €374M in own funds is not freely deployable—it functions more like restricted capital than strategic firepower, constraining the "tech company" narrative. Second, valuation dependency on growth: at 6.4× ARR, any ARR growth deceleration from 50%+ to below 20% would compress the multiple substantially, particularly if group profitability is delayed beyond 2027. Third, undisclosed loss ratio: the core actuarial risk—whether health claims are tracking at, above, or below the management-stated 100% pass-through target—is never disclosed, making independent risk assessment impossible without data room access. Fourth, governance concerns: Belfius occupies the dual role of lead Series F investor and primary distribution partner in Belgium, which creates a potential conflict of interest in valuation and governance, a concern explicitly raised by independent analyst Matteo Carbone. Fifth, public sector concentration: 32% of net ARR growth in FY2024 came from public sector contracts (e.g., Ministry of Economy and Finance), and any reversal or non-renewal of public sector wins would disproportionately impair reported ARR momentum. [CV024, CV025, CV026, CV027, CV028, CV029]

8.4 Bull, Base, and Bear Scenarios

Scenario analysis anchors on three variables: ARR trajectory, path to group profitability, and exit-multiple compression. In the bull case, Alan achieves its €1B ARR target in 2026 and delivers group-level profitability in FY2027 as guided; international markets (Belgium, Spain, Canada) scale to 30%+ of ARR by end-2027; and the company commands a 10× forward ARR multiple at a 2029 IPO—implying a potential equity value of €12–15B on €1.5B+ ARR. In this scenario, early Series E investors (€2.7B entry) see approximately 5× and Series F investors (€4B entry) see approximately 3–4× on invested capital. In the base case, ARR growth moderates to 30–35% in 2026 (€1–1.1B ARR), group profitability arrives in FY2028 rather than 2027, and exit multiple compresses to 6–8× forward ARR at a 2029–2030 exit—implying an equity value of €7–10B, or 40–100% upside from the current €5B mark. Series F investors see 1.75–2.5× return. In the bear case, ARR growth decelerates sharply to below 20% due to public sector churn or loss ratio deterioration, group profitability is delayed to 2030+, the Solvency II review (January 2027 implementation) creates additional capital requirements, and the market reprices Alan as a carrier at 2–3× ARR (implying a valuation of €2–3.3B on €1B ARR)—a 33–60% decline from the current mark. This bear case is structurally possible if the Carbone critique proves correct at scale: that Alan's fundamental economics, stripped of the tech premium, resemble a marginally-profitability niche insurer rather than a technology platform. The Solvency II review is a real structural risk: EIOPA's revised framework, scheduled for implementation on 30 January 2027, may alter capital formula requirements, and Alan's SCR coverage buffer (3.6×), while currently ample, must be maintained under potentially revised calibrations. [CV034, CV035, CV036, CV037, CV038, CV039]

8.5 Recommendation, Thesis-Break Triggers, and Final Diligence Asks

Our recommendation is TRACK. At €5B post-money, Alan's valuation is defensible but not yet investment-grade for a new position without resolution of key evidence gaps. The business trajectory—France profitable, ARR +53% YoY, losses as a share of ARR at 3.3%, and a 3.6× Solvency II buffer—validates the growth story but does not resolve core actuarial and financial reporting gaps (no loss ratio, no IFRS audited accounts, no per-country P&L). The €5B private mark implies a 25–100% premium to public market comps on the same revenue base (Lemonade at P/S 5.14× is the closest public analog, though still loss-making). This premium is justifiable if: (a) group profitability arrives in FY2027 as guided, (b) the loss ratio remains near 100% as claimed, and (c) Alan successfully scales Belgium, Spain, and Canada without triggering material Solvency II capital calls. An upgrade to RECOMMEND would require: confirmation of FY2027 group-level profitability ahead of schedule; publication of IFRS-audited consolidated financial statements or independent actuarial sign-off on loss ratio; and clear evidence that public sector ARR is not concentrated in any single ministry. A downgrade to AVOID would be triggered by: material loss ratio divergence (claims exceeding 105% of premiums consistently), ARR growth decelerating below 20% in any two consecutive quarters, or a regulatory action by ACPR or the Belgian/Spanish supervisors. The governance concentration risk (founders and employees holding voting majority with 40% capital) is a standard European growth-stage structure but creates secondary liquidity risk for early investors; any prospective investor should seek pro-rata rights, anti-dilution provisions, and board representation commensurate with ownership. [CV041, CV042, CV043, CV044, CV045]

8.6 Exhibits